Miroslaw Jan Lubecki is a senior executive with over 20 years of experience in the healthcare sector, predominantly within Europe’s international arena. A medical doctor by education, he started his career in a university hospital. After working for 2 years in the field of cardiology/ intensive care he completed his business education and transitioned into the pharmaceutical industry, first working at Brocades Pharma and then Yamanouchi Pharma in Poland. His career path has led him through various organizational levels within pharmaceutical sales and marketing, from Medical Representative to Commercial Director. To advance his career further, Miroslaw Jan Lubecki moved to Austria in 2007 beginning initially as Marketing & Sales Director and most recently taking on the role of General Manager for Astellas Pharma Austria, responsible for the country organization and its performance. In addition he served as Board Member for Astellas Pharma’s E6 (Europe) region and was a member of the European Oncology Steering Committee.
Having had European, Regional and Country management responsibilities, Miroslaw Jan Lubecki is an experienced and successful leader who is used to working with cross-cultural and cross-functional teams in dynamic business environments. In addition to the medical degree, he holds an executive MBA from the University of Montreal/Calgary and completed his PhD studies in Psychology, specializing in Intercultural Psychology and Organizational Behavior. He is multi-lingual and speaks Polish, German, English, Russian and Italian.
At AOP Orphan, Miroslaw Jan Lubecki will first concentrate on preparing the organization for future challenges including expansion into new markets. Simultaneously he will prepare the launch of new products in the areas of Hematology and Gastroenterology.
About AOP Orphan
AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. With special competencies in the area, the company researches, produces and sells innovative treatments for rare conditions, concentrating on three treatment areas: Hematology and Oncology, Cardiology and Pulmonology, and Neurology and Psychiatry. AOP Orphan is active on an international level with an export ratio of 70% and is one of the leading players in the Orphan Drug market.